These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24397175)

  • 1. [Diabetic nephropathy].
    Araki S
    Nihon Rinsho; 2013 Nov; 71(11):2010-4. PubMed ID: 24397175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.
    Kurita N; Ito T; Shimizu S; Hirata T; Uchihara H
    Diabetes Care; 2014 Sep; 37(9):e198-9. PubMed ID: 25147262
    [No Abstract]   [Full Text] [Related]  

  • 4. Authors' reply to Tufan and colleagues and Boucaud-Maitre.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 Jun; 353():i3188. PubMed ID: 27267359
    [No Abstract]   [Full Text] [Related]  

  • 5. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia.
    Boucaud-Maitre D
    BMJ; 2016 Jun; 353():i3186. PubMed ID: 27267596
    [No Abstract]   [Full Text] [Related]  

  • 6. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
    Ligueros-Saylan M; Foley JE; Schweizer A; Couturier A; Kothny W
    Diabetes Obes Metab; 2010 Jun; 12(6):495-509. PubMed ID: 20518805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
    Jojima T; Aso Y
    Nihon Rinsho; 2013 Nov; 71(11):1987-92. PubMed ID: 24397171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Forst T; Dworak M; Berndt-Zipfel C; Löffler A; Klamp I; Mitry M; Pfützner A
    Diabetes Obes Metab; 2013 Jun; 15(6):576-9. PubMed ID: 23384119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].
    Mukai E; Fujimoto S; Inagaki N
    Nihon Rinsho; 2011 May; 69(5):907-11. PubMed ID: 21595280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.
    Schweizer A; Dejager S; Foley JE; Couturier A; Ligueros-Saylan M; Kothny W
    Diabetes Obes Metab; 2010 Jun; 12(6):485-94. PubMed ID: 20518804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of medication adherence in patients with type 2 diabetes mellitus.
    Curkendall SM; Thomas N; Bell KF; Juneau PL; Weiss AJ
    Curr Med Res Opin; 2013 Oct; 29(10):1275-86. PubMed ID: 23815104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 19. [Progress in diagnosis of and therapy for diabetic complication--diabetic nephropathies].
    Haneda M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):773-8. PubMed ID: 19472530
    [No Abstract]   [Full Text] [Related]  

  • 20. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
    Kothny W; Shao Q; Groop PH; Lukashevich V
    Diabetes Obes Metab; 2012 Nov; 14(11):1032-9. PubMed ID: 22690943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.